Cancer Chemotherapy and Biotherapy Principles and Practice

by Chabner, Bruce A.; Longo, Dan L.

• ISBN13: 9780781756280
• ISBN10: 0781756286
• Edition: 4th
• Format: Hardcover
• Copyright: 2005-11-01
• Publisher: LWW

Summary

Updated to include the newest drugs and those currently in development, this Fourth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition provides expanded coverage of monoclonal antibodies, molecularly targeted drugs, vaccines, cell based therapies, growth factors, and pharmacogenetics.

Table of Contents

Preface	vii
Acknowledgment	ix
Contributors	xi
Clinical Strategies for Cancer Treatment: The Role of Drugs	1	(14)
Bruce A. Chabner
Preclinical Aspects of Cancer Drug Discovery and Development	15	(16)
Paula Krosky
Melinda Hollingshead
Robert Shoemaker
Edward A. Sausville
Pharmacokinetics	31	(14)
Jerry Collins
Jeffrey G. Supko
Infertility After Cancer Chemotherapy	45	(25)
Angela Bradbury
Richard L. Schilsky
Carcinogenesis of Anticancer Drugs	70	(21)
Lawrence S. Blaszkowsky
Charles Erlichman
Antifolates	91	(34)
Brian P. Monahan
Carmen J. Allegra
5-Fluoropyrimidines	125	(58)
Jean L. Grem
Cytidine Analogues	183	(29)
David P. Ryan
Rocio Garcia-Carbonero
Bruce A. Chabner
Purine Antimetabolites	212	(17)
Kenneth R. Hande
Hydroxyurea	229	(8)
Luis Paz-Ares
Ross C. Donehower
Bruce A. Chabner
Antimicrotubule Agents	237	(46)
Eric K. Rowinsky
Clinical and High-Dose Alkylating Agents	283	(27)
Kenneth D. Tew
O. Michael Colvin
Roy B. Jones
Nonclassic Agents	310	(22)
Henry S. Friedman
Steven D. Averbuch
Joanne Kurtzberg
Cisplatin, Carboplatin, and Oxaliplatin	332	(12)
Eddie Reed
Bleomycin	344	(15)
John S. Lazo
Bruce A. Chabner
Antitumor Antibiotics	359	(12)
Edwin W. Willems
Kees Nooter
Jaap Verweij
Topoisomerase I--Targeting Drugs	371	(43)
Alex Sparreboom
William C. Zamboni
Anthracyclines and Anthracenediones	414	(37)
James H. Doroshow
Topoisomerase II Inhibitors: The Epipodophyllotoxins, Acridines, and Ellipticines	451	(25)
Yves Pommier
Francois Goldwasser
Asparaginase	476	(8)
Bruce A. Chabner
Alison M. Friedmann
Delivering Anticancer Drugs to Brain Tumors	484	(18)
Maciej M. Mrugala
Tracy T. Batchelor
Jeffrey G. Supko
Food and Drug Administration Role in Oncology Product Development	502	(14)
Thomas G. Roberts Jr.
Central Venous Catheters: Care and Complications	516	(13)
Rachel P. Rosovsky
David J. Kuter
Pharmacogenetics	529	(20)
Jeanne Fourie
Robert B. Diasio
New Targets for Anticancer Therapeutics	549	(30)
A. Dimitrios Colevas
Orit Scharf
Janet E. Dancey
S. Percy Ivy
Len Neckers
Bennett Kaufman
Richard Swerdlow
Bisphosphonates	579	(8)
Matthew R. Smith
Thalidomide and Its Analogs for the Treatment of Hematologic Malignancies, Including Multiple Myeloma, and Solid Tumors	587	(18)
Paul Richardson
Constantine S. Mitsiades
Teru Hideshima
Kenneth Anderson
Inhibitors of Tumor Angiogenesis	605	(16)
Anaadriana Zakarija
William J. Gradishar
Proteasome Inhibitors	621	(20)
Owen A. O'Connor
Molecular Targeted Drugs and Growth Factor Receptor Inhibitors	641	(25)
Jeffrey W. Clark
Antibody Therapies of Cancer	666	(33)
David A. Scheinberg
Deborah A. Mulford
Joseph G. Jurcic
Richard P. Junghans
George Sgouros
Interferons	699	(19)
Daniel J. Lindner
Kevin L. Taylor
Frederic J. Reu
Paul A. Masci
Ernest C. Borden
Adoptive Cellular Therapies	718	(21)
Carl H. June
Cancer Vaccines	739	(8)
Glenn Dranoff
Hematopoietic Growth Factors	747	(20)
William P. Petros
Interleukins	767	(42)
Gheath Alatrash
Ronald M. Bukowski
Charles S. Tannenbaum
James H. Finke
Hormonal Therapy for Breast Cancer	809	(38)
Peter F. Lebowitz
Sandra M. Swain
Index	847